444 related articles for article (PubMed ID: 25445930)
1. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
2. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.
Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF
Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586
[TBL] [Abstract][Full Text] [Related]
3. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
4. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
6. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.
Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF
Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991
[TBL] [Abstract][Full Text] [Related]
7. [Clinical profile of roflumilast].
Izquierdo Alonso JL
Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast: a novel treatment for chronic obstructive pulmonary disease.
Reid DJ; Pham NT
Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
[TBL] [Abstract][Full Text] [Related]
13. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
14. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
Yan JH; Gu WJ; Pan L
Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
[TBL] [Abstract][Full Text] [Related]
19. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Tashkin DP
Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]